
SANARA MEDTECH INC
SMTINASDAQTrading Snapshot
- Day Range
- $33.85 β $34.84
- 52-Week Range
- $16.05 β $35.95
- Volume
- $3.81B
- Avg Volume
- $2.84B
- Shares Outstanding
- 9.2M
- Next Earnings
- Sep 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $103M
- Last Q Revenue
- $28M
- P/E Ratio
- β
- P/S Ratio
- 3.9x
- EPS (TTM)
- $-3.88
- Dividend Yield
- β
Why Investors Own SMTI
- βHigh-growth profile β revenue up +22.1% YoY with expanding US Equity exposure.
- βHealthy economics β 74% gross margin and 19% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SANARA MEDTECH INC
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
SANARA MEDTECH INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift SMTI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
SANARA MEDTECH INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.